loading page

Treatment of B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classical Hodgkin’s Lymphoma (Gray Zone Lymphoma) in Children and Young Adults: A Case Series
  • +6
  • Egor Volchkov,
  • Mariia Senchenko,
  • Dmitriy Abramov,
  • Edvard Biyuachuev,
  • Olga Prudnikova,
  • Evgenii Nikitin,
  • Laima Beljaeva,
  • Dmitry Konovalov,
  • Natalia Myakova
Egor Volchkov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology Oncology and Immunology

Corresponding Author:[email protected]

Author Profile
Mariia Senchenko
Dmitry Rogachev National Medical Research Center of Pediatric Hematology Oncology and Immunology
Author Profile
Dmitriy Abramov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology Oncology and Immunology
Author Profile
Edvard Biyuachuev
S. P. Botkin City Clinical Hospital of Moscow Department of Health
Author Profile
Olga Prudnikova
Clinical Oncological Dispensary, 9, Bldg. 1, Zavertyaeva St., Omsk, 644013
Author Profile
Evgenii Nikitin
Dmitry Rogachev National Medical Research Center of Pediatric Hematology Oncology and Immunology
Author Profile
Laima Beljaeva
Dmitry Rogachev National Medical Research Center of Pediatric Hematology Oncology and Immunology
Author Profile
Dmitry Konovalov
Federal Center for Pediatric Hematology, Oncology and Immunology, named by D.Rogachev
Author Profile
Natalia Myakova
Federal Center for Pediatric Hem|Onc|Imm
Author Profile

Abstract

B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin’s lymphoma (cHL) is a rare malignant disease that develops from mature B cells. This disease was first recognized as a distinct entity in 2008. It is most common in the 20 to 40 age group and rare in children. Currently, there are no clear criteria for diagnosis and standard therapy for such patients. According to the literature, it is possible to use treatment regimens applied for both aggressive B-cell lymphomas and Hodgkin’s lymphoma. The addition of anti-CD20/CD30 targeted agent to standard therapy may be effective, given the expression of these markers by tumor cells. In this article, we present the clinical and morphological characteristics of patients with unclassifiable B-cell lymphoma with features intermediate between diffuse large B-cell lymphoma and cHL, diagnosed at our center, including 4 patients at the onset of the disease in childhood